NASDAQ: LNTH ยท Specialty & Generic Drug Manufacturers
Lantheus Holdings (LNTH) fair value and price range
As of 14 Nov 2026, Faircurve's model values Lantheus Holdings (LNTH) at $100.47 a share. The stock last closed at $101.72, which puts the model's fair value 1.2% below the price. The inputs behind this valuation are under review, so no verdict is shown.
- The latest balance sheet shows far less debt than the quarter before, with no matching repayment.
Revalued . Price is the close of 16 Nov 2026. Lantheus Holdings, Inc.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $100.47, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $101.72 is 1.2% above it. The inputs behind this valuation are under review, so no verdict is shown.
What's nextNext report on 25 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give LNTH?
The calibrated range for LNTH over 63 trading days is $80.35 to $119.36. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $63.13 to $156.60. In 49% of the simulations the fair value came out above the price the model ran on.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does LNTH report earnings, and how has the stock reacted?
Lantheus Holdings's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across LNTH's last 8 reports, ignoring direction, was 9.4%.
What the options market has priced for a month's move in LNTH
How does LNTH score on business quality?
Lantheus Holdings's overall quality score is 70 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 94 | 17.7%ROIC | 1.8% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 95 | 1.46xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 22 | 0.5%Revenue growth, trailing | 1.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 86 | 1.5%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 79 | -0.13xNet debt / EBITDA | 2.54x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 16 | 12.7 ptsEBITDA margin downside volatility, 5y | 1.5 pts |
How does LNTH compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Lantheus Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AMRX Amneal Pharmaceuticals, Inc. | $21.23 | $19.34 | -8.9% | Low evidence grade |
| ALKS Alkermes plc | $46.53 | $46.51 | 0.0% | Fairly valued |
| ELAN Elanco Animal Health Incorporated | $26.41 | $25.34 | -4.1% | Low evidence grade |
| VTRS Viatris Inc. | $20.74 | $26.77 | +29.1% | Undervalued |
| SUPN Supernus, Inc. | $28.83 | $29.86 | +3.6% | Low evidence grade |
| ANIP ANI Pharmaceuticals, Inc. | $70.89 | $78.16 | +10.3% | Fairly valued |
| PAHC Phibro Animal Health Corporation | $35.02 | $36.25 | +3.5% | Low evidence grade |
| PCRX Pacira BioSciences, Inc. | $36.48 | $36.71 | +0.6% | Low evidence grade |
What the comparable companies' multiples alone would give for LNTH, the peer-implied price, is $91.24 a share on this run. The fair value weighs that against the company's own multiple.
All specialty & generic drug manufacturer stocks ranked by gap to fair value
Lantheus Holdings at a glance
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents.
- Market value
- $6.6B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $1.6B
- Consensus revenue growth, next fiscal year
- -3.1%
- Analysts with estimates
- 3
- Beta to the US market
- 0.51
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Lantheus Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for LNTH was $100.83. As of 14 Nov 2026 it is $100.47, a change of -0.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Lantheus Holdings's valuation
Is Lantheus Holdings stock undervalued or overvalued?
Faircurve's model puts LNTH's fair value at $100.47 a share against a last close of $101.72, as of 14 Nov 2026. The inputs behind this valuation are under review, so no verdict is shown.
What is LNTH's fair value?
$100.47 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $63.13 to $156.60.
What price range does the model give LNTH?
$80.35 to $119.36 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Lantheus Holdings report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has LNTH moved on past earnings reports?
Across its last 8 reports the median two session move was 9.4%, ignoring direction. The largest was -24.5% around the report of 6 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for LNTH is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.